CSI Market
Sign In | Register

Inmed Pharmaceuticals Inc (INM) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access INM quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Inmed Pharmaceuticals Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
12 Months 		(Jun 30 2025) (Mar 31 2024) (Jun 30 2023) (Jun 30 2022)
Operating Activities
Income-36.93
Depreciation & amortization0.21
Amortization of Other Assets0.16
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.19
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.01
Share-based Compensation0.11
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.07
Interest Incomeaccrued Received On Shortterm Investments-
Unrealized Gain On Foreign Exchange-
Operating Lease Right Of Use Asset Amortization Expense0.29
Interest Income Short Term Investment Other0.00
Unrealized Loss On Foreign Currency Derivatives Before Tax0.00
Goodwill And Intangible Asset Impairment-
Increase Decrease In Contract With Customer Liability-0.29
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.62
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other-0.08
Other Working Capital0.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities26.79
Discontinued operations0.33
Net Cash flow from Operating Activities-8.64
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Sale Of Shortterm Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments to Acquire Loans Receivable0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.14
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.23
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Settlement Of Debt Upon Acquisition Of Subsidiary-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents8.91
Private Placement Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.64
Total Cash Flow-8.55
4 historic quarters locked

Sign in to unlock the full Inmed Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Inmed Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-098419

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License